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Abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed for elderly patients,
particularly after a hip fracture. However, we are not clear about the effect of NSAIDs on the risk of a second hip
fracture because of confounding factors.
Methods: This was a Taiwan National Health Insurance Research Database-based study using propensity-score
matching (PSM) to control for confounding. Enrollees were selected from patients with a hip fracture during
1996–2004 and followed longitudinally until December 2009. After PSM for comorbidities and bisphosphonate
therapy, 94 patients with a second hip fracture were assigned to the Cases group and 461 without it to the
Controls group. The target drugs are NSAIDs; paracetamol and dexamethasone are used for comparison.
Results: The correlation between the mean daily-dose (MDD) ratios of NSAIDs and the probability values of
the current statistical tests were highly negative (Pearson’s r = −0.920, P = 0.003), which indicated that the
higher the MDD ratios, the greater the risks of a second hip fracture. A Kaplan-Meier survival analysis showed
a time-dependent trend of increasing risk of a second hip fracture in patients taking NSAIDs (P < 0.001).
Moreover, patients ≥60 years old had a higher risk of a second hip fracture than did those <60 and taking
the NSAIDs diclofenac (P = 0.016) and celecoxib (P = 0.003) and the corticosteroid dexamethasone (P = 0.018),
but not those taking analgesic paracetamol (P = 0.074).
Conclusions: We conclude that taking NSAIDs after a fragility hip fracture dose- and time-dependently
significantly increases the risk of a second hip fracture, especially in elderly patients. To lower the risk of a
second hip fracture, any underlying causes for excessively using NSAIDs should be treated and thus fewer
NSAIDs prescribed after a first hip fracture.
Keywords: Non-steroidal anti-inflammatory drugs, Fragility hip fracture, Second hip fracture, Population-based
study, Propensity-score matching
Background
The occurrence of a second hip fracture and subsequent
mortality in patients with a fragility hip fracture is high
[1–6]. Ryg et al., using Denmark’s National Hospital
Discharge Register for the period 1997 to 2001,
explored this sequela of osteoporosis [2]. They found
that patients with a fragility hip fracture had twice the
risk of a second hip fracture, and that they had a 5-year
mortality of approximately 60 %. Moreover, the esti-
mated 1-year risk of a second hip fracture, whether in
Western or Asian populations, should vary from 2 to
5 %, depending on the age of the patient [3]. These
findings highlight the importance of formulating and
proposing a tertiary strategy for osteoporosis to prevent
a subsequent hip fracture [3, 7].
We previously reported that, in addition to age, female
gender, and comorbidities, the prolonged use of analgesics,
e.g., paracetamol, and anti-inflammatory medications,
e.g., dexamethasone and NSAIDs (non-steroidal anti-
inflammatory drugs), is a significant risk factor for a
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second hip fracture after hip fracture surgery [3]. Para-
cetamol, dexamethasone, and NSAIDs are commonly
prescribed. Paracetamol is a mild analgesic and dexa-
methasone a potent anti-inflammatory corticosteroid.
NSAIDs have analgesic effects and, in higher doses,
anti-inflammatory effects because they inhibit the
cyclooxygenase-2 (COX-2) activity and then reduce the
synthesis of prostaglandins [8]. Prostaglandins are
potent, multifunctional regulators of bone metabolism,
which can stimulate and inhibit bone resorption and
formation [9–13]. In general, NSAIDs are supposed to
reduce the rate of bone loss, and thus improve bone min-
eral density (BMD) and prevent a fragility hip fracture
[14–16], but conflicting results have also been published
[17, 18]. Additional analyses that use different approaches
to control for confounding are necessary to clarify the
degree of association and/or causal link between NSAIDs
and the risk of a second hip fracture.
During the last decade, interest in determining the
degree of association and/or causal link between medi-
cations and the risk of a fragility hip fracture has grown
[17, 19]. However, establishing the degree of association
and/or causal link is difficult because observational
studies are notoriously vulnerable to the effect of dif-
ferent types of confounding [20]. It is well recognized
that the estimate of causality obtained by comparing
cases with controls could be prejudiced because of
problems such as selection bias or other systematic
errors [20–22]. Rosenbaum and Rubin developed and
popularized the propensity-score matching (PSM)
method for observational (non-experimental) studies,
in which only a small subset of controls comparable to
cases must be selected [21]; PSM reduces the selection
bias by balancing groups on the probability of being
treated based on specific covariates [22]. Many studies
have used the PSM method to control for confounding.
In the current study, we used the PSM method to con-
trol for confounding and aimed to determine the strength
of the association between NSAIDs and the risk for a sec-
ond hip fracture in patients after hip fracture surgery. We
also explored the age-specific risk of a second hip fracture
in these patients.
first hip fracture s/p surgery
from the NHIRD 1996 -2004
(n = 1,552)




1:5 Matching on propensity
score for comorbidities and 
bisphosphonate therapy 





Without second hip fracture
in 2005-2009
(n = 1,451)
Fig. 1 A flowchart of the patient selection process
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Methods
Data source
The Taiwan National Health Insurance (NHI) program, a
single-payer universal program that began in March 1995,
now enrolls more than 99 % of the population. Its claims
data for reimbursements provide one of the world’s largest
datasets for health research. The National Health Insurance
Research Database (NHIRD), derived from the payment
system of the National Health Insurance Administration
(NHIA) and maintained by the National Health Research
Institute (NHRI) in Taiwan, provides vital information for
research. The accuracy of the NHIRD diagnoses of major
disorders, e.g., stroke and acute coronary syndrome, has
been validated [23]. The NHIRD includes patient demo-
graphics, disease diagnoses, medical care institution names,
medical expenditure, and prescription claims data. For each
medical expenditure reimbursement, the types of medical
services and details of medical orders and costs are
recorded. In the present study, data were obtained from the
Longitudinal Health Insurance Database (LHID2000), a
representative subset of 1 million patients from the NHIRD
(http://nhird.nhri.org.tw/). All the identifiers of individual
patients and medical care providers (medical profes-
sionals and institutions) are deleted by the NHIA before
data are transferred to the NHIRD. Institutional review
board (IRB) approval, an agreement to approve, moni-
tor, and review biomedical and behavioral researches
involving humans, is pre-approved by the NHRI for de-
identified data.
Study design and participants
This study was a nationwide population-based observa-
tional study using PSM to control valuables that are mea-
sured at baseline for confounding. The study participants
were selected from the NHIRD/LHID2000 registry covering
the period from January 1996 to December 2004 and
followed longitudinally until December 31, 2009. The study
participants were identified from the database based on the
following criteria: (1) a diagnosis code of hip fracture (ICD-
9-CM diagnosis codes 820.0–820.9); (2) a procedure code
of internal fixation or partial hip replacement (ICD-9-CM
procedure codes 79.15, 79.35, and 81.52); and (3) pa-
tients 40 years old or older. The first admission date for
a hip fracture was defined as the index date. After delet-
ing the records of patients who died between 1996 and
2004 (n = 7), 1,545 patients with a hip fracture were in-
cluded and followed longitudinally until the end of the
study. During the follow-up period, patients with a sec-
ond hip fracture were selected as Cases (n = 94). Four
hundred sixty-one of 1,451 patients were selected as
Controls using 1:5 matching on propensity scores for
comorbidities and bisphosphonate therapy. By matching
variables that would otherwise confound comparisons
between groups, the PSM method effectively creates
similar case and control sets from an existing dataset
for an observational study [22]. The Cases group con-
sisted of 94 patients with a second hip fracture and the
Controls group of 461 without. The flowchart of patient
selection process is presented in Fig. 1.
Drug exposure and primary and secondary endpoints
NSAIDs, identified based on the anatomical therapeutic
chemical (ATC) classification system [24], are known to
work in two ways: (1) analgesic effects at lower doses
and (2) anti-inflammatory effects at higher doses. To
clarify the dose-response relationship between NSAIDs
and the risk of a second hip fracture, we included para-
cetamol (a pure analgesic) and dexamethasone (a cor-
ticosteroid and potent anti-inflammatory drug) in the
current study. The prescription history of each patient
for every medication studied was summarized as either
exposed or not exposed during the paired case and con-
trol periods. For each patient, to explore the possible
dose response, we also estimated the mean daily dose
Table 1 Characteristics of Cases and Controls by 1:5 matching on







Diabetes mellitus 34 (36.2) 147 (31.9) 0.420
Arterial hypertension 63 (67.0) 311 (67.5) 0.934
Hyperlipidemia 20 (21.3) 102 (22.1) 0.856
Coronary heart disease 34 (36.2) 158 (34.3) 0.725
Myocardial infarction 1 (1.1) 8 (1.7) 0.639
Cardiac dysrhythmia 18 (19.2) 71 (15.4) 0.367
PAODa 3 (3.2) 21 (4.6) 0.554
Kidney dysfunction 2 (2.1) 4 (0.9) 0.282
Stroke/TIAb 4 (4.3) 26 (5.6) 0.589
Dementia 11 (11.7) 60 (13.0) 0.728
Parkinson’s disease 11 (11.7) 44 (9.5) 0.523
COPDc 24 (25.5) 113 (24.5) 0.834
Osteoporosis 25 (26.6) 133 (28.9) 0.659
Arthritis 33 (35.1) 145 (31.5) 0.489
Bisphosphonate therapy, no (%) 26 (27.7) 123 (26.7) 0.855
Propensity score, mean points (SD) 0.17 (0.04) 0.16 (0.03)
(Min, Max) (0.10, 0.43) (0.08, 0.31)
Age, mean years (SD) 74.0 (2.6) 69.5 (3.6) <0.001*
Sex, no. (%) 0.995
Male 33 (35.1) 162 (35.1)
Female 61 (64.9) 299 (64.9)
a PAOD, peripheral arterial occlusive disease; b TIA, transient ischemic attack;
c COPD, chronic obstructive pulmonary disease
* P value < 0.05 is significant and all analysis was done by logistic regression
model in SAS 9.2
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(MDD) by calculating the cumulative dose of medica-
tions prescribed and then divided that number by the
number of days in the period. The primary endpoint of
this study was to determine the strength of association
between drug exposure and the occurrence of a second
hip fracture in patients after hip fracture surgery. For
our secondary endpoint, information on the age-specific
risk of a second hip fracture in these patients was col-
lected for further analysis.
Statistical analysis
A χ2 test was used to analyze categorical data. For
numerical variables, Student’s t test was used for
between-group comparisons. Univariate and multivariate
analyses using a stepwise logistic regression model were
done to detect significant predictive factors of a second
hip fracture after hip fracture surgery. Between-group
comparisons were done by estimating the odds ratio
(OR) and the 95 % confidence interval (CI) in a logistic
regression model. To examine the effects of MDD on
the risk of a second hip fracture, the Pearson correlation
test was used. The 15-year second hip fracture-free sur-
vival rate after hip fracture surgery was estimated using
the Kaplan-Meier method and the log-rank test. The
cumulative hazard function was also used and the propor-
tional hazards assumption was met for each parameter in
additional models. In Cox-regression proportional hazards
survival analysis, potential predictors in the forced-entry
model were used as covariates (e.g., age, gender, and co-
morbidities). Significance was set at p < 0.05 (two-sided).
SAS 9.2 (SAS, Inc., Cary, NC, USA) was used for all
analyses.
Table 2 Medication use (paracetamol, dexamethasone, and
NSAIDs) in Cases and Controls
Variables Cases (n = 94) Controls (n = 461) P Value
Paracetamol, no. (%) 34 (35.8) 83 (18.1) 0.026*
MDDa, mg (SD) 605.6 (103.4) 496.0 (127.9) 0.009*
Aspirin, no. (%) 9 (9.9) 46 (10.0) 0.491
MDD, mg (SD) 105.6 (57.9) 101.2 (53.9) 0.569
Diclofenac, no. (%) 39 (41.7) 71 (15.4) <0.001*
MDD, mg (SD) 206.9 (59.4) 116.1 (99.1) <0.001*
Ibuprofen, no. (%) 26 (28.1) 93 (20.1) <0.001*
MDD, mg (SD) 439.9 (115.9) 257.6 (85.0) <0.001*
Naproxen, no. (%) 7 (7.4) 30 (6.5) 0.643
MDD, mg (SD) 485.2 (184.9) 451.0 (150.1) 0.583
Nabumetone, no. (%) 8 (9.0) 47 (10.1) 0.217
MDD, mg (SD) 1055.7 (479.3) 1014.7 (609.7) 0.506
Etodolac, no. (%) 13 (13.6) 54 (11.8) 0.416
MDD, mg (SD) 552.0 (50.1) 590.5 (33.9) 0.563
Celecoxib, no. (%) 22 (23.1) 44 (9.5) <0.001*
MDD, mg (SD) 305.3 (98.8) 198.2 (100.1) <0.001*
Rofecoxib, no. (%) 11 (11.6) 57 (12.3) 0.086
MDD, mg (SD) 70.6 (6.6) 75.7 (9.8) 0.057
Dexamethasone, no. (%) 37 (39.4) 76 (16.5) <0.001*
MDD, mg (SD) 9.8 (7.5) 4.0 (3.9) <0.001*
a MDD, mean daily dose
* P value < 0.05 is significant and all analysis was done by logistic regression
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Fig. 2 Correlation between the fold increase of the mean daily dose (MDD) of NSAIDs and of the log value of the probability of the current statistical
hypothesis tests
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Results
From 1996 through 2004, 555 patients ≥40 years who
sustained a hip fracture and underwent hip fracture sur-
gery were selected and enrolled in this study. There were
no significant differences in comorbidities and bisphos-
phonate therapy between the Cases and Controls
(Table 1). Patients with a second hip fracture after hip
fracture surgery were older (mean age: 74.0 years vs.
69.5 years, P < 0.001). There were, however, no signifi-
cant differences in gender distribution.
Patients in the Cases group had taken significantly
more paracetamol and had a higher MDD than did those
in the Controls group (35.8 % vs. 18.1 %, P = 0.026;
605.6 mg vs. 496.0 mg, P = 0.009, respectively); the same
was true for diclofenac (41.7 % vs. 15.4 %, P < 0.001;
206.9 mg vs. 116.1 mg, P < 0.001), ibuprofen (28.1 % vs.
20.1 %, P < 0.001; 439.9 mg vs. 257.6 mg, P < 0.001), cel-
ecoxib (23.1 % vs. 9.5 %, P < 0.001; 305.3 mg vs.
198.2 mg, P < 0.001), and dexamethasone (39.4 % vs.
16.5 %, P < 0.001; 9.8 mg vs. 4.0 mg, P < 0.001). There were,
however, no significant between-group differences for
aspirin, naproxen, nabumetone, etodolac, or rofecoxib (all
P ≥ 0.057) (Table 2). There was a highly negative correlation
between the MDD ratios and the probability values of the
current statistical tests (Pearson’s r = −0.920, P = 0.003 for
NSAIDs only) (Fig. 2); thus, the higher the MDD ratios
were, the greater risks of a second hip fracture the patients
had.
Using the PSM method to control for confounding,
age but not gender was identified as a significant pre-
dictor of a second hip fracture (Table 1). For every 1-
year increase in age, there was at least a 2.4 % increase
in the risk of a second hip fracture, and at least a 13.0 %
increase for every 5-year increase in age (all P ≤ 0.044)
(Table 3). Overall, the risk ratio (RR) was 14.8 % higher
for female patients than for male patients (P < 0.001)
(Table 4). Using 40–49-year-olds as the reference group,
the RRs for a second hip fracture were significantly
higher for those 60–69, 70–79, and ≥80 (all P ≤ 0.040),
but not for those 50–59 (P = 0.627).
The 15-year survival analyses showed that male
patients ≥60 were significantly more likely to have a sec-
ond hip fracture after their hip fracture surgery than
those <60 (P = 0.019). This was not true for the total
group of patients or for the group of female patients
(both P ≥ 0.092) (Fig. 3a–c). For the group as a whole,
the RR for a second hip fracture was significantly (P <
0.001) and time-dependently higher for patients taking
paracetamol, NSAIDs, and dexamethasone (Fig. 3d).
Kaplan-Meier survival analyses also showed that the RR for
a second hip fracture was significantly higher for patients
≥60 than for those <60 exposed to diclofenac (P = 0.016)
(Fig. 3e), celecoxib (P = 0.003) (Fig. 3f), and dexamethasone
(P = 0.018) (Fig. 3g), but not to paracetamol (P = 0.074)
(Fig. 3h).
Discussion
We confirmed that patients who take NSAIDs after hip
fracture surgery have a significantly higher risk for a second
hip fracture than do patients who do not take NSAIDs.
Moreover, the positive association was dose- and time
(years after first hip fracture surgery)-dependent for the
group as a whole and dose- and age-dependent for patients
Table 3 Odds ratio estimates in logistic regression model for
second hip fracture in patients after hip fracture surgery





Total vs. total 1.026 1.004 1.047 0.017*
Female vs. female 1.024 1.001 1.050 0.044*
Male vs. male 1.030 1.002 1.059 0.038*
Female vs. male 1.190 1.005 1.214 <0.001*
Five-year age difference
Total vs. total 1.134 1.022 1.259 <0.001*
Female vs. female 1.130 1.010 1.278 <0.001*
Male vs. male 1.162 1.013 1.333 <0.001*
Female vs. male 1.220 1.010 1.430 <0.001*
* P value < 0.05 is significant and all analysis was done by logistic regression
model in SAS 9.2
Table 4 Analysis of parameter estimates in lognormal regression model for second hip fracture in patients after hip fracture surgery
Parameters Estimate SE 95 % Wald CI Chi- Pr > RR
Lower Upper Square ChiSq
Sex Male - - - - - - 1.000
Female 1.001 0.342 0.113 1.772 2.80 <0.001* 1.148
Age 40–49 - - - - - - 1.000
50–59 −0.401 0.488 −1.357 0.556 0.85 0.627 0.670
60–69 0.756 0.357 0.057 1.455 3.55 0.040* 2.129
70–79 0.820 0.255 0.319 1.320 4.05 0.020* 2.270
≥80 1.013 0.265 0.494 1.531 8.87 0.005* 2.752
* P value < 0.05 is significant and all analysis was done by logistic regression model in SAS 9.2
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Fig. 3 Kaplan-Meier survival estimates with a second hip fracture (SHFx) as an endpoint. Survival free of a second hip fracture for a total patients,
b male patients, c female patients, d patients who took and did not take paracetamol, NSAIDs, and dexamethasone, and e patients who took
paracetamol, f diclofenac, g celecoxib, and h dexamethasone. * P < 0.05
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≥60. Furthermore, the higher the MDD of NSAIDs was,
the greater the risk of a second hip fracture was. These
findings highlight the importance of changing the treatment
strategy of elderly patients after their first hip fracture.
To the best of our knowledge, this is the first report
on confirming the association between taking NSAIDs
and the risk of a second hip fracture in patients after hip
fracture surgery. We previously reported that age, female
gender, comorbidities, and the prolonged use of analge-
sics and anti-inflammatory medications are all significant
risk factors for a second hip fracture after hip fracture
surgery, but that bisphosphonate therapy was protective
[3]. However, in an observational study, there are many
confounders that usually distort the relationship between
an exposure and an outcome [20–22, 25]. The PSM
method is useful in these circumstances because it pro-
vides a neutral weighting formula that yields unbiased
estimates of the effects of treatment. In the current
study, we thus used the propensity score model for con-
trolling variables that are measured at baseline. After
using the PSM for controlling comorbidity and bisphos-
phonate therapy, age but not gender remains to be a sig-
nificant risk factor for the occurrence of a second hip
fracture in patients after hip fracture surgery.
Although users of NSAIDs are reported to have higher
BMD than do non-users [19, 26, 27], the effect of
NSAIDs on the risk of a hip fracture is still not under-
stood [14–18]. Two studies found that the hip fracture
risk was lower in patients taking NSAIDs [14, 17]. In
contrast, a report based on the Danish Osteoporosis Pre-
vention Study (DOPS) showed that users of NSAIDs had
more hip fractures than expected [18]. Leaving aside the
debate whether NSAIDs increase the risk of a first hip
fracture, the authors highlight the issue of tertiary
prevention for osteoporosis because of the healthcare
resources constraint [2, 3]. Our data revealed that the
higher the MDD ratios of NSAIDs, the greater the likeli-
hood of a second hip fracture in patients after hip frac-
ture surgery. One possible explanation is that, when
prolonged, the anti-inflammatory effects of NSAIDs at
higher doses elevate the risks of a second hip fracture.
Another explanation is that NSAID users have an
impaired gait because of the sequelae of their index fra-
gility hip fracture. No matter what the mechanism is, we
recommend that NSAIDs should be cautiously pre-
scribed for patients who have just undergone hip frac-
ture surgery, particularly for elderly patients. As with
other drugs prescribed for elderly patients [17, 28, 29],
the most judicious approach is to restrict NSAIDs to sit-
uations in which their benefits clearly overweigh their
risks, and to use them only after any underlying causes
for excessive drug use have been adequately treated and
potentially safer alternatives have been tried. When
treatment with NSAIDs is necessary, the lowest feasible
dose should be used for the shortest duration required
to achieve the desired effect [28, 29].
This study has some limitations. First, it is retrospective.
Second, it might still have an uncontrolled selection and
recall bias despite our using stratification and the PSM
method to control for confounders. For example, the pres-
ence of a diagnosis of comorbidity is different from con-
trolling for the severity of the disease, which may be
expected to be different in older individuals. Third, the
risk of a second hip fracture may be underestimated
because we included the survival rate after the index hip
fracture only and also excluded patients who died from
any cause between 1996 and 2004. We could not account
for patients who sustained a hip fracture 2 years before
the index date and thus wrongly had their second hip frac-
ture classified as an index hip fracture despite their having
no hips at risk. Finally, we lacked information on what
caused the higher exposure rate and higher MDD of
NSAIDs in our patients after their hip fracture surgery.
Conclusions
In conclusion, taking NSAIDs after hip fracture surgery
significantly increases the risk of a second hip fracture.
The positive association is dose- and time-dependent
for all patients and age-dependent for the elderly.
Because of a global deterioration of health conditions
in elderly patients after a fragility hip fracture [17], they
are usually prescribed significantly more drugs, espe-
cially analgesics and anti-inflammatory agents. Physi-
cians should limit prescribing NSAIDs to situations
with a positive benefit-risk balance and use them only
after the underlying cause for excessively using NSAIDs
have been adequately treated and potentially safer alter-
natives have failed. The lowest feasible dose for the
shortest duration required to achieve the desired effect
should be considered. If more long-range treatment
with NSAIDs is necessary and inevitable, more aggres-
sive monitoring and prevention for another fragility
fracture is warranted [30, 31], because long-term
NSAIDs treatment might contribute to rises in the risk
for a second hip fracture.
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